Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial-Reference-Cited by-同舟云学术

Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial

Published:2016-11-16 Issue:4 Volume:77 Page:385-395
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Armstrong Andrew J.¹,Humeniuk Michael S.¹,Healy Patrick²,Szmulewitz Russell³,Winters Carolyn¹,Kephart Julie¹,Harrison Michael R.¹,Martinez Elia³,Mundy Kelly¹,Halabi Susan²,George Daniel¹

Affiliation:

1. Divisions of Medical Oncology and Urology; Departments of Medicine and Surgery; Duke Cancer Institute; Durham North Carolina

2. Department of Biostatistics; Duke University; Durham North Carolina

3. Department of Medicine; University of Chicago; Chicago Illinois

Funder

Active Biotech

US Department of Defense Prostate Cancer Clinical Trials Consortium

Publisher

Wiley

Subject

Urology,Oncology

Reference27 articles.

1. The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer;Isaacs;Expert Opin Investig Drugs,2010

2. Tasquinimod in the treatment of castrate-resistant prostate cancer-Current status and future prospects;Mehta;Ther Adv Urol,2016

3. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides;Bjork;PLoS Biol,2009

4. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein;Cheng;J Exp Med,2008

5. S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells;Hermani;Exp Cell Res,2006

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Third generation quinoline‐3‐carboxamide transcriptional disrupter of HDAC4, HIF‐1α, and MEF‐2 signaling for metastatic castration‐resistant prostate cancer;The Prostate;2023-08-09

2. Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?;Cancers;2022-01-16

3. Progress in the development of kynurenine and quinoline-3-carboxamide-derived drugs;Expert Opinion on Investigational Drugs;2020-09-02

4. Biological and therapeutic advances in the pursuit of effective immunotherapy for prostate cancer;Current Opinion in Urology;2020-01

5. Prostate cancer immunotherapy;Current Opinion in Urology;2018-01